OxFORD Asset Management LLP cut its holdings in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 64.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 36,710 shares of the biopharmaceutical company’s stock after selling 65,518 shares during the quarter. OxFORD Asset Management LLP’s holdings in Alexion Pharmaceuticals were worth $5,150,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Rathbone Brothers plc raised its holdings in shares of Alexion Pharmaceuticals by 2.5% in the 2nd quarter. Rathbone Brothers plc now owns 2,040 shares of the biopharmaceutical company’s stock valued at $248,000 after purchasing an additional 50 shares in the last quarter. Seven Bridges Advisors LLC raised its holdings in shares of Alexion Pharmaceuticals by 2.1% in the 2nd quarter. Seven Bridges Advisors LLC now owns 2,638 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 53 shares in the last quarter. Geneva Advisors LLC raised its holdings in shares of Alexion Pharmaceuticals by 0.7% in the 2nd quarter. Geneva Advisors LLC now owns 11,408 shares of the biopharmaceutical company’s stock valued at $1,388,000 after purchasing an additional 82 shares in the last quarter. Evercore Wealth Management LLC raised its holdings in shares of Alexion Pharmaceuticals by 8.1% in the 2nd quarter. Evercore Wealth Management LLC now owns 1,665 shares of the biopharmaceutical company’s stock valued at $202,000 after purchasing an additional 125 shares in the last quarter. Finally, Wealthsource Partners LLC raised its holdings in shares of Alexion Pharmaceuticals by 4.4% in the 2nd quarter. Wealthsource Partners LLC now owns 3,002 shares of the biopharmaceutical company’s stock valued at $365,000 after purchasing an additional 126 shares in the last quarter. Institutional investors own 94.16% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at $108.90 on Wednesday. Alexion Pharmaceuticals, Inc. has a one year low of $96.18 and a one year high of $149.34. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. The company has a market cap of $24,360.00, a price-to-earnings ratio of 22.28, a P/E/G ratio of 1.19 and a beta of 1.18.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.32 by $0.12. Alexion Pharmaceuticals had a net margin of 14.57% and a return on equity of 12.55%. The firm had revenue of $859.00 million for the quarter, compared to analyst estimates of $864.34 million. During the same period last year, the business earned $1.23 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 7.5% compared to the same quarter last year. analysts predict that Alexion Pharmaceuticals, Inc. will post 4.82 earnings per share for the current fiscal year.

A number of equities research analysts have recently weighed in on the stock. Leerink Swann restated a “buy” rating and issued a $182.00 price objective on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research lowered shares of Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. Royal Bank Of Canada assumed coverage on shares of Alexion Pharmaceuticals in a report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price objective on the stock. BMO Capital Markets restated an “outperform” rating and issued a $173.00 price objective (up from $168.00) on shares of Alexion Pharmaceuticals in a report on Wednesday, September 13th. Finally, Evercore ISI assumed coverage on shares of Alexion Pharmaceuticals in a report on Wednesday, August 16th. They issued an “in-line” rating and a $137.00 price objective on the stock. Five equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $155.06.

TRADEMARK VIOLATION NOTICE: This story was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another publication, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/06/oxford-asset-management-llp-trims-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.